Research programme: diabetes/obesity therapies - ChemGenex Pharmaceuticals/Merck-Sante

Alternative Names: CXS-102 SelS; CXS-121 SGIP1; CXS-203 PSARL

Latest Information Update: 30 Oct 2008

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

30 Oct 2008 Discontinued - Preclinical for Obesity in Australia (unspecified route)
30 Oct 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in Australia (unspecified route)
20 Jul 2007 Preclinical development is ongoing

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com